• Je něco špatně v tomto záznamu ?

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

P. Pautier, I. Vergote, F. Joly, B. Melichar, E. Kutarska, G. Hall, A. Lisyanskaya, N. Reed, A. Oaknin, V. Ostapenko, Z. Zvirbule, E. Chetaille, A. Geniaux, M. Shoaib, JA. Green,

. 2017 ; 27 (2) : 258-266.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010929

OBJECTIVE: Advanced/metastatic or recurrent endometrial cancer has a poor prognosis. Malignant endometrial tissue has high steroid sulphatase (STS) activity. The aim of this study was to evaluate STS as a therapeutic target in patients with endometrial cancer. METHODS: This was a phase 2, multicenter, international, open-label, randomized (1:1), 2-arm study of the STS inhibitor oral irosustat 40 mg/d versus oral megestrol acetate 160 mg/d in women with advanced/metastatic or recurrent estrogen receptor-positive endometrial cancer. The primary end point was the proportion of patients without progression or death 6 months after start of treatment. Secondary end points included progression-free survival, time to progression, overall survival, and safety. RESULTS: Seventy-one patients were treated (36 with irosustat, 35 with megestrol acetate). The study was prematurely stopped after futility analysis. Overall, 36.1% and 54.1% of patients receiving irosustat or megestrol acetate had not progressed or died at 6 months, respectively. There were no statistically significant differences between irosustat and megestrol acetate in response and overall survival rates. Irosustat patients had a median progression-free survival of 16 weeks (90% confidence interval, 9.0-31.4) versus 40 weeks (90% confidence interval, 16.3-64.0) in megestrol acetate patients. Treatment-related adverse events occurred in 20 (55.6%) and 13 (37.1%) patients receiving irosustat or megestrol, respectively. Most adverse events in both groups were grade 1 or 2. CONCLUSIONS: Although irosustat monotherapy did not attain a level of activity sufficient for further development in patients with advanced/recurrent endometrial cancer, this study confirms the activity of hormonal treatment (megestrol acetate) for this indication.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010929
003      
CZ-PrNML
005      
20180404142415.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/IGC.0000000000000862 $2 doi
035    __
$a (PubMed)27870712
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pautier, Patricia $u *Gustave Roussy Cancer Campus, Villejuif, France; †Leuven Cancer Institute, Leuven, Belgium; ‡Centre François Baclesse, Caen, France; §Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; ‖Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland; ¶Leeds Cancer Centre, St James University Hospital, Leeds, United Kingdom; #City Clinical Oncology Dispensary, St Petersburg, Russia; **Gartnavel General Hospital, Glasgow, United Kingdom; ††Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; ‡‡Vilnius University Institute of Oncology, Vilnius, Lithuania; §§Oncology Centre of Latvia, Riga East University Hospital, Riga, Latvia; ‖‖Ipsen Innovation, Les Ulis, France; and ¶¶Clatterbridge Cancer Centre, University of Liverpool, Bebington, Merseyside, United Kingdom.
245    12
$a A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer / $c P. Pautier, I. Vergote, F. Joly, B. Melichar, E. Kutarska, G. Hall, A. Lisyanskaya, N. Reed, A. Oaknin, V. Ostapenko, Z. Zvirbule, E. Chetaille, A. Geniaux, M. Shoaib, JA. Green,
520    9_
$a OBJECTIVE: Advanced/metastatic or recurrent endometrial cancer has a poor prognosis. Malignant endometrial tissue has high steroid sulphatase (STS) activity. The aim of this study was to evaluate STS as a therapeutic target in patients with endometrial cancer. METHODS: This was a phase 2, multicenter, international, open-label, randomized (1:1), 2-arm study of the STS inhibitor oral irosustat 40 mg/d versus oral megestrol acetate 160 mg/d in women with advanced/metastatic or recurrent estrogen receptor-positive endometrial cancer. The primary end point was the proportion of patients without progression or death 6 months after start of treatment. Secondary end points included progression-free survival, time to progression, overall survival, and safety. RESULTS: Seventy-one patients were treated (36 with irosustat, 35 with megestrol acetate). The study was prematurely stopped after futility analysis. Overall, 36.1% and 54.1% of patients receiving irosustat or megestrol acetate had not progressed or died at 6 months, respectively. There were no statistically significant differences between irosustat and megestrol acetate in response and overall survival rates. Irosustat patients had a median progression-free survival of 16 weeks (90% confidence interval, 9.0-31.4) versus 40 weeks (90% confidence interval, 16.3-64.0) in megestrol acetate patients. Treatment-related adverse events occurred in 20 (55.6%) and 13 (37.1%) patients receiving irosustat or megestrol, respectively. Most adverse events in both groups were grade 1 or 2. CONCLUSIONS: Although irosustat monotherapy did not attain a level of activity sufficient for further development in patients with advanced/recurrent endometrial cancer, this study confirms the activity of hormonal treatment (megestrol acetate) for this indication.
650    _2
$a senioři $7 D000368
650    _2
$a hormonální protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D018931
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a nádory endometria $x farmakoterapie $x metabolismus $x patologie $7 D016889
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a megestrolacetát $x škodlivé účinky $x terapeutické užití $7 D019290
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x metabolismus $x patologie $7 D009364
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a kyseliny sulfonové $x škodlivé účinky $x terapeutické užití $7 D013451
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vergote, Ignace
700    1_
$a Joly, Florence
700    1_
$a Melichar, Bohuslav
700    1_
$a Kutarska, Elzbieta
700    1_
$a Hall, Geoffrey
700    1_
$a Lisyanskaya, Anna
700    1_
$a Reed, Nicholas
700    1_
$a Oaknin, Ana
700    1_
$a Ostapenko, Valerijus
700    1_
$a Zvirbule, Zanete
700    1_
$a Chetaille, Eric
700    1_
$a Geniaux, Agnès
700    1_
$a Shoaib, Muhammad
700    1_
$a Green, John A
773    0_
$w MED00009896 $t International journal of gynecological cancer official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 27, č. 2 (2017), s. 258-266
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27870712 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142455 $b ABA008
999    __
$a ok $b bmc $g 1288414 $s 1007741
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 27 $c 2 $d 258-266 $i 1525-1438 $m International journal of gynecological cancer $n Int J Gynecol Cancer $x MED00009896
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace